These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
527 related items for PubMed ID: 21481127
1. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Fonseca V, Gill J, Zhou R, Leahy J. Diabetes Obes Metab; 2011 Sep; 13(9):814-22. PubMed ID: 21481127 [Abstract] [Full Text] [Related]
2. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. Janka HU, Plewe G, Busch K. J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653 [Abstract] [Full Text] [Related]
6. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes. Owens DR, Bolli GB, Charbonnel B, Haak T, Landgraf W, Porcellati F, Traylor L, Kautzky-Willer A. Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412 [Abstract] [Full Text] [Related]
7. Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials. Owens DR, Traylor L, Dain MP, Landgraf W. Diabetes Res Clin Pract; 2014 Nov; 106(2):264-74. PubMed ID: 25195151 [Abstract] [Full Text] [Related]
8. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P. Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331 [Abstract] [Full Text] [Related]
9. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Owens DR, Traylor L, Mullins P, Landgraf W. Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788 [Abstract] [Full Text] [Related]
10. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia. Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N. Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078 [Abstract] [Full Text] [Related]
13. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study. Schiel R, Müller UA. Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):58-64. PubMed ID: 17973208 [Abstract] [Full Text] [Related]
14. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D. Ann Intern Med; 2008 Oct 21; 149(8):531-9. PubMed ID: 18936501 [Abstract] [Full Text] [Related]
15. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. Meneghini LF, Traylor L, Schwartz SL. Endocr Pract; 2010 Oct 21; 16(4):588-99. PubMed ID: 20350924 [Abstract] [Full Text] [Related]
17. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints. Prescrire Int; 2005 Oct 21; 14(79):187-93. PubMed ID: 16285076 [Abstract] [Full Text] [Related]
18. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea. Kang YM, Jung CH, Lee SH, Kim SW, Song KH, Kim SG, Kim JH, Cho YM, Park TS, Ku BJ, Koh G, Kim DM, Lee BW, Park JY. Diabetes Metab J; 2019 Aug 21; 43(4):432-446. PubMed ID: 31237133 [Abstract] [Full Text] [Related]
19. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Miser WF, Arakaki R, Jiang H, Scism-Bacon J, Anderson PW, Fahrbach JL. Clin Ther; 2010 May 21; 32(5):896-908. PubMed ID: 20685497 [Abstract] [Full Text] [Related]
20. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use. Terauchi Y, Riddle MC, Hirose T, Koyama M, Cheng X, Takahashi Y, Bolli GB. Diabetes Obes Metab; 2018 Nov 21; 20(11):2541-2550. PubMed ID: 29888454 [Abstract] [Full Text] [Related] Page: [Next] [New Search]